Pfizer and AstraZeneca vaccines approved for booster scheme
We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info
The agreement with Caelum Biosciences has given the FTSE 100 group access to another potentially profitable treatment that is undergoing late-stage trials. This also comes after AstraZeneca completed a major takeover of pharmaceutical company Alexion worth £39 billion, which will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs. Cambridge-based AstraZeneca is one of the largest drugs groups in the world.
This also comes after AstraZeneca completed a major takeover of pharmaceutical company Alexion worth £39 billion, which will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs.
Cambridge-based AstraZeneca is one of the largest drugs groups in the world.
The Alexion takeover is its biggest-ever acquisition since the company was first created in 1999 through the joining of Sweden’s Astra with Britain’s Zeneca companies.
Caelum, the New Jersey-based biotechnology company, has developed a treatment for AL amyloidosis, which is a life-threatening disease that damages the heart and kidneys.
The disease causes abnormal proteins called amyloids to build up in human organs and disrupt their normal functions.
This can cause widespread and progressive organ damage and high mortality rates, with death most frequently occurring as a result of cardiac failure
It affects around 20,000 people in the UK, U.S, France, Germany, Italy, Spain.
The drug has now won “fast-track” status for regulatory review in the states.
Given the name CAEL-101, the treatment is currently being evaluated in the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical programme in combination with standard-of-care (SoC) therapy in AL amyloidosis.
Marc Dunoyer, 68, Alexion’s chief executive, said of AL amyloidosis: “With a median survival time of less than 18 months following diagnosis, there is an urgent need for new treatments for this devastating disease.”
Caelum will be folded into AstraZeneca’s Alexion division, and Alexion will pay over £100million to buy the remaining stake in Caelum that it does not own already.
It will make future payments worth over a quarter of a million pounds linked to performance measures.
Alexion also bought a minority holding in Caelum two years ago.
‘Forget UK fuel crisis!’ China energy shortage to spark global impact [INSIGHT]
Germany faces worse gas crisis as Britain outsmarts Putin [REVEAL]
Archaeologists find Hitler’s 3,300mph ‘superweapon’ buried in Kent [REPORT]
As a leader in rare diseases for nearly 30 years, Alexion has been focused on and is committed to serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines.
Last week, AstraZeneca also announced positive clinical data on two of its oncology drugs being developed to treat prostate and breast cancer.
The company also announced a deal with VaxEquity to develop drugs using the RNA technology used in Moderna and Pfizer Covid vaccines.
A recent COVID-19 clinical trial in the US on the AstraZeneca vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65 and older, in a study published on Wednesday.
Source: Read Full Article